Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Does etanercept induce uveitis?

Literature DB >> 12812909

Does etanercept induce uveitis?

A R Reddy, O C Backhouse.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2003 PMID： 12812909 PMCID： PMC1771735 DOI： 10.1136/bjo.87.7.925

Source DB: PubMed Journal: Br J Ophthalmol ISSN： 0007-1161 Impact factor: 4.638

× No keyword cloud information.

11 in total

1. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.

Authors: Jörn Kekow; Tobias Welte; Udo Kellner; Thomas Pap
Journal: Arthritis Rheum Date: 2002-03

Review 2. T-cell function and migration. Two sides of the same coin.

Authors: U H von Andrian; C R Mackay
Journal: N Engl J Med Date: 2000-10-05 Impact factor: 91.245

Review 3. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire.

Authors: A Cope; R Ettinger; H McDevitt
Journal: Res Immunol Date: 1997-06

4. Etanercept therapy in children with treatment-resistant uveitis.

Authors: A Reiff; S Takei; S Sadeghi; A Stout; B Shaham; B Bernstein; K Gallagher; T Stout
Journal: Arthritis Rheum Date: 2001-06

5. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.

Authors: J R Smith; R D Levinson; G N Holland; D A Jabs; M R Robinson; S M Whitcup; J T Rosenbaum
Journal: Arthritis Rheum Date: 2001-06

6. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Authors: Jennifer D Gorman; Kenneth E Sack; John C Davis
Journal: N Engl J Med Date: 2002-05-02 Impact factor: 91.245

Review 7. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Authors: J Braun; J Sieper; M Breban; E Collantes-Estevez; J Davis; R Inman; H Marzo-Ortega; H Mielants
Journal: Ann Rheum Dis Date: 2002-12 Impact factor: 19.103

8. Leukocytoclastic vasculitis due to etanercept.

Authors: N A Galaria; V P Werth; H R Schumacher
Journal: J Rheumatol Date: 2000-08 Impact factor: 4.666

Review 9. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

Authors: Roy Fleischmann; Imran Iqbal; Pallavi Nandeshwar; Andres Quiceno
Journal: Drug Saf Date: 2002 Impact factor: 5.606

10. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat.

Authors: A F De Vos; M A Van Haren; C Verhagen; R Hoekzema; A Kijlstra
Journal: Exp Eye Res Date: 1995-12 Impact factor: 3.467

20 in total

1. Peripheral visual field loss following treatment with etanercept.

Authors: L J Clifford; J D Rossiter
Journal: Br J Ophthalmol Date: 2004-06 Impact factor: 4.638

Review 2. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors: Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-08-25 Impact factor: 3.117

10. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

Authors: M Rudwaleit; E Rødevand; P Holck; J Vanhoof; M Kron; S Kary; H Kupper
Journal: Ann Rheum Dis Date: 2008-07-28 Impact factor: 19.103

Does etanercept induce uveitis?

1. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.

Review 2. T-cell function and migration. Two sides of the same coin.

Review 3. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire.

4. Etanercept therapy in children with treatment-resistant uveitis.

5. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.

6. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Review 7. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

8. Leukocytoclastic vasculitis due to etanercept.

Review 9. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

10. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat.

1. Peripheral visual field loss following treatment with etanercept.

Review 2. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Review 3. Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Review 4. Non-infectious pediatric uveitis: an update on immunomodulatory management.

5. Psoriasis onset during infliximab treatment: description of two cases.

Review 6. Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?

7. Adalimumab in the therapy of uveitis in childhood.

8. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series.

Review 9. [TNFalpha inhibitors in the treatment of uveitis].

10. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.